Affiliation: DSM Nutritional Products Ltd.

Dr. Kyoko Koshibu received her PhD in Neurobiology at University of Pittsburgh, where she investigated the brain developmental changes in a rodent model of Schizophrenia. Following, she received post-doctoral trainings at ETH Zurich in Switzerland, where she explored the epigenetic regulation of cognition, and Queensland Brain Institute in Australia, where she explored the neural physiology underlying PTSD. She then moved on to various leading R&D roles in industry, including UCB Pharma as a lab head for new target drug discovery program for neurodegenerative diseases, Philip Morris International as a study director to investigate the effects of natural nicotinic alkaloids on cognition and neurodegenerative diseases, and Nestlé Research as a group leader to develop nutritional solutions for early brain development. Currently, she is a global innovation manager at DSM Nutritional Products Ltd. in Switzerland, where she is leading global I&R pipeline for brain health dietary supplements.